See inside every stock. Pro
S&P 5007,723▲ 0.60%Nasdaq26,478▲ 1.18%Dow Jones52,378▲ 0.03%Nasdaq 10029,651▲ 1.29%VIX17.52▼ 4.73%US Dollar102.35▲ 0.39%Gold spot4,006▲ 0.30%WTI101.32▲ 1.42%
← B8FK page
XStocksXray
Market X-Ray report · 27 October 2026

Biofrontera AG (B8FK)

Deutsche Börse Xetra · Germany · prices in EUR · close of 27 Oct 2026

Key indicators

Last closeEUR 2.980
52-week range2.210 – 5.100
Return, 1 month / 3 months−14.4% / +16.0%
Return, 1 year / 3 years+11.6% / −74.2%
TrendUptrend
RSI (14)48
Volatility (1 year)57.9%
Worst drawdown (1 year)-28.2%
Average daily value traded0.01M EUR
Dividend yield–

Market X-Ray price-based

55/ 100 · High confidence · ahead of 53% of stocks on this exchange
Trend70
Momentum83
Stability (higher is calmer)36
Liquidity14
Income–

Five-year price chart navy: price · brown: 200-day average

-0.2210.8221.8732.9143.952021-112023-022024-052025-082026-10

About the company

Biofrontera AG is a German pharmaceutical company focused on dermatology. It develops and markets topical treatments for skin conditions, most notably a light-activated gel used in photodynamic therapy for actinic keratosis, a precancerous skin lesion. The company also supplies the special lamp used to activate its treatment during therapy sessions. Its customers are dermatologists and clinics, mainly in Europe and the United States, and it is based in Leverkusen, Germany.

On this site Biofrontera AG appears as a stock on the Deutsche Börse Xetra (Germany), code B8FK, with prices in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

Biofrontera AG (B8FK) trades on the Deutsche Börse Xetra in Germany. It last closed at EUR 2.980 on 27 October 2026.

Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 327 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price rose 11.6% and over the last three months it rose 16.0%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
Biofrontera AG (B8FK)

The five lenses in numbers each metric is ranked against the other stocks on Deutsche Börse Xetra

Lens and metricValueScoreReading
Trend70 · FairMixed trend against its averages.
Above 200-day average15.1%
From 52-week high-26.2%
Momentum83 · StrongRising faster than most stocks on this exchange.
3-month return16.0%
6-month return22.6%
12-month return, skipping the last month30.3%
Stability (higher is calmer)36 · WeakVolatile, with deep drawdowns.
Volatility, 1 year (lower is calmer)57.9%
Worst drawdown, 1 year (smaller is calmer)-28.2%
Liquidity14 · WeakThinly traded: prices can jump and exits can be hard.
Average daily value traded0.01M EUR
Zero-volume days1.7%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Momentum: Rising faster than most stocks on this exchange.

Weak spots

  • Stability (higher is calmer): Volatile, with deep drawdowns.
  • Liquidity: Thinly traded: prices can jump and exits can be hard.

Returns

1 week+0.7%
1 month−14.4%
3 months+16.0%
6 months+22.6%
1 year+11.6%
3 years−74.2%
5 years−94.2%

Signals

50-day / 200-day average2.859 / 2.588
Golden / death cross (60 days)Golden, 24 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.231

Technical summary

DailyNeutral7 bullish · 4 neutral · 5 bearish
WeeklyStrongly bullish9 bullish · 1 neutral · 2 bearish
MonthlyNeutral4 bullish · 1 neutral · 3 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Deutsche Börse Xetra; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 28 Oct 2026